CheckMate 602: A Phase 3, Open-Label, Randomized Trial of Combinations of Nivolumab, Elotuzumab, Pomalidomide, and Dexamethasone in Relapsed or Relapsed and Refractory Multiple Myeloma

Antitumor immune responses in multiple myeloma (MM) may be suppressed through overexpression of the programmed death-1 (PD-1) receptor on effector cells and the PD-L1 ligand on myeloma cells (Liu et al, Blood 2007; G örgün et al, Clin Cancer Res 2015). Nivolumab, an anti–PD-1 monoclonal antibody (mAb), blocks PD-1 checkpoint signaling to enhance antitumor responses, and shows modest activity as monotherapy for relapsed/refractory (RR) MM (Lesokhin et al, J Clin Oncol 2016). Elotuzumab, an anti-SLAMF7 mAb, di rectly activates natural killer (NK) cells and mediates antibody-dependent cellular cytotoxicity.

Source: Clinical Lymphoma, Myeloma and Leukemia - September 1, 2017 Category: Hematology Authors: Sagar Lonial, Paul Richardson, Donna Reece, Hesham Mohamed, Suresh Shelat, Jes ús San Miguel Source Type: research